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Background Pathogen inactivation methods for platelet concentrates are increas-
ingly being used in blood banks worldwide. In vitro studies have demonstrated
its effects on storage lesion, but little routine quality control data on blood bank-
ing outcomes have been reported.
Materials and Methods Swirling of distributed products was monitored before
and after implementation of Intercept pathogen inactivation. Metabolic parame-
ters pH, glucose and lactic acid were determined in a random cohort of expired
pathogen-inactivated products. Storage lesion indicators in apheresis concen-
trates with premature low swirling were compared to concentrates with normal
swirling.
Results During validation for implementing Intercept pathogen inactivation, pH
and glucose levels decreased faster in apheresis platelet concentrates with high
platelet content than with low platelet content or than in pathogen-inactivated
pooled buffy coat-derived products. In routine products, glucose exhaustion was
more often found in apheresis compared to buffy coat-derived platelet concen-
trates despite 3–7% more plasma carryover in the former. Annual incidence of
premature low swirling increased significantly by 50% following implementation
of pathogen inactivation implementation for apheresis but not for pooled buffy
coat platelet concentrates. In addition, apheresis concentrates with premature low
swirling had a significantly higher median platelet count (50 9 1011) than unaf-
fected products (35 9 1011).
Conclusion The risk of increased storage lesion rates following Intercept patho-
gen inactivation is higher for apheresis than for buffy coat-derived platelet con-
centrates, especially when platelet contents are higher than 50 9 1011.
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Introduction
The impact of (Intercept) pathogen inactivation on plate-
lets has been studied extensively in experimental condi-
tions, but quality control data from routine use are less
common. Experimental research has demonstrated that
quality control parameters [1] of Intercept pathogen-inac-
tivated platelets generally are within predefined ranges
[2–4] but with a significant impact on in vitro function
[5]. This is caused by irreversible changes in the platelet
plasma membrane which affect subsequent intracellular
signal transduction [6]. Clinical studies have demon-
strated significantly lower corrected count increments at
1 and 24 h, shorter transfusion intervals and increased
transfusions of Intercept-treated platelets compared to
standard concentrates [7, 8]. However, no differences in
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mortality, clinically significant bleeding or severe bleed-
ing were found in a meta-analysis of these trials [9]. Of
note, the practical impact on blood component processing
is significant because several adaptations in the produc-
tion chain are required to meet acceptance criteria [10].
Here, we describe the results of our extended QC pro-
gramme, obtained during the first year of routine patho-
gen inactivation use. Our quality control routine includes
monitoring of pH, glucose and lactic acid on a random
subset of expired products as well as monitoring swirling
score of every platelet concentrate to be issued. In addi-
tion, during the first year of routine pathogen inactiva-
tion use, apheresis platelet concentrates with ‘premature’
low swirling score (i.e. before expiration day) were trans-
ferred to the research centre for further analysis and
compared to expired day 6 platelet concentrates with
normal swirling. This quality control series indicated
increased chances of storage lesion following Inter-
cept pathogen inactivation particularly for apheresis pla-
telet concentrates with platelet contents higher than
50 9 1011.
Materials and methods
Apheresis platelet concentrate production
Single-donor platelet concentrates were collected by
apheresis using the Trima Accel Automated Blood Collec-
tion System (Terumo BCT, Lakewood, CO, USA). Final
product volumes and platelet content were set to comply
with the Intercept pathogen inactivation method guard
bands of ‘Large Volume’ bag sets (Table 1). Platelet addi-
tive solution (SSP+, Macopharma, Tourcoing, France) was
added aiming for a fixed plasma carryover of 40% (v/v).
In case the donor was eligible for double-dose apheresis,
volumes above 610 mL were set, allowing splitting to the
compliant volume ranges after collection. These double-
dose concentrates were split to two separate ‘Large
Volume’ bag sets prior to Intercept treatment. ‘Dual stor-
age’ bag sets were used specifically when a paediatric
platelet product (16 9 1011 platelets) was to be derived
from the donation. In that case, splitting took place right
after Intercept treatment. All apheresis platelet concen-
trates were stored in the storage containers of the Inter-
cept illumination set.
Buffy coat-derived platelet concentrate production
Concentrates prepared by the buffy coat method were
from whole blood donations. Six buffy coats were manu-
ally pooled as described [5, 11], supplemented with SSP+
additive solution and then treated with Intercept patho-
gen inactivation prior to storage. In this case, a fixed
amount of additive solution of 280 ml was added, result-
ing in a variable plasma content between 33% and 37%
(v/v). All buffy coat-derived platelet concentrates were
stored in the storage containers of the Intercept illumina-
tion set.
Laboratory methods
Standard quality control included determination of pH,
glucose and lactic acid levels of a random cohort of
expiring buffy coat and apheresis-derived platelet con-
centrates.
Prior to distribution, platelet concentrates were rou-
tinely assessed for swirling yielding an integral score
between 0 and 3. Products with a low swirling score ≤1
were considered inappropriate for issuing. On the day of
assessment, these product numbers were introduced in the
electronic tracking system. All products with premature
low swirling score were thus counted in the year before
(2014) and after (2015) introduction of Intercept pathogen
inactivation.
Apheresis platelet concentrates with premature low
swirling score were further analysed for platelet count,
Table 1 Projected parameters for platelet concentrates prepared by apheresis
Yield (31011) Collected vol (ml) Collected conc (3103/ll) Final vol (ml) Final conc (3103/ll)
37 128 2890 193 1156
42 136 3087 205 1235
47 144 3264 217 1306
52 152 3420 229 1368
57 157 3625 236 1450
72 260 2769 391 1108
80 260 3077 390 1231
85 272 3125 408 1250
vol = volume; conc = concentration.
All concentrates are automatically supplemented with SSP+ additive solution.
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platelet concentration, mean platelet volume (MPV), pH,
lactic acid, glucose and expression of surface receptors by
flow cytometry. These laboratory analyses were per-
formed on the day of assessment, thus excluding those
flagged during weekends. These concentrates were com-
pared to regularly expiring apheresis products assessed
(day 6) with a swirling score ≥2.
Platelet counts and MPV were measured on an auto-
mated haematology analyser (pocH-100i; Sysmex, Kobe,
Japan). Metabolic parameters were measured on a point-
of-care blood gas analyser (Siemens RapidPoint 500,
Munich, Germany), but pH was assessed separately using
a calibrated glass electrode at 21°C. Flow cytometry was
performed essentially as described [5]. In brief, expression
of P-selectin (anti-CD62P~phycoerythrin, BD Biosciences,
Erembodegem, Belgium), activated integrin aIIbb3
(PAC1~fluorescein, BD Biosciences) and phosphatidylser-
ine (Annexin V~Peridinin chlorophyll-Cy55; BD Bio-
sciences) was determined using an acoustic focusing flow
cytometer (Attune, Life Technologies, Carlsbad, CA, USA).
Platelets were incubated with labelled antibodies or
ligand for 10 min at room temperature in 10 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)
buffer, pH 74 with 09% (w/v) NaCl (HBS), 1 mM MgSO4
and 5 mM KCl, then diluted a 1000-fold immediately
before readout as described before [12]. For Annexin V
measurements, buffers were supplemented with 2 mM
CaCl2. For measurements of integrin aIIbb3 activation on
stimulated platelets, the PAR1 agonist thrombin-related
activating hexapeptide SFLLRN (TRAP, Sigma-Aldrich, St
Louis, MO, USA) was added at 30 lM, or cross-linked
collagen-related peptide at 5 lg/ml (CRP, University of
Cambridge, Cambridge, United Kingdom). The signals of
the isotype antibody controls were used to set threshold
gates including 05% of 10 000 negative events. For
annexin V gating, samples were incubated with annexin V
in the absence of ionized calcium. Median fluorescence
intensities and percentage positive events were determined
of 10 000 cells staining positive for the platelet marker
CD61 (anti-CD61~allophycocyanin, Life Technologies).
Statistics
Sample means were compared by t-test or Mann–Whitney
for parametric and non-parametric data sets, respectively.
Chi-square analysis was used to assess contingency
tables. A significance level of 005 was used. Computa-
tional analysis was with Prism (GraphPad Software Inc,
La Jolla, CA, USA).
Results
Apheresis concentrates with high platelet content
show signs of increased storage lesion
Experimental process validation to implement Intercept
pathogen inactivation showed that the pH decreased fas-
ter in apheresis concentrates compared to pooled buffy
coat platelet concentrates (Fig. 1a). Apheresis units with
low platelet content (<17 9 1011) intended for paediatric
use did not show this decline suggesting platelet content
plays a role as well. Glucose levels on day 6 were more-
over lower in the high content apheresis products
(Fig. 1b) compared to pooled buffy coat platelet concen-
trates, despite 3–7% more plasma carryover. All concen-
trates had normal swirling throughout the study. This was
confirmed in routine use because the incidence of glucose
levels below detection limit was higher in apheresis (5/20)
than in buffy coat-derived (1/75) products (Fig. 2). The
median (range) platelet content of these products was not
different (apheresis 37 (34–54) 9 1011 vs. buffy coat
39 (30–54) 9 1011, P = 071).
Fig. 1 Metabolic parameters of apheresis and buffy coat-derived platelet concentrates in a validation study to implement Intercept pathogen inactiva-
tion. (a) The decrease in pH over a six day storage period of individual Intercept pathogen-inactivated platelet concentrates prepared by apheresis for
paediatric use (<16 9 1011, n = 3) (Χ), for adult use (>30 9 1011, n = 6) (●) or prepared by pooling of buffy coats (n = 6) (○) is shown in function
of the initial platelet count. (b) Glucose concentrations were determined on day 6 of storage for the same individual Intercept pathogen-inactivated
platelet concentrates described in panel (a). The dotted horizontal line represents the lower limit (11 mM) of detection.
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Incidence of low swirling was increased in
concentrates prepared by apheresis but not by the
buffy coat method
In the first year following implementation of Intercept
pathogen inactivation, the number of apheresis products
with a low swirling score (≤1) increased by 50% (63/
12 492) compared to the previous year without pathogen
inactivation (42/12 931, P = 0030, Chi-square). In con-
trast, the incidence of low swirling score in platelet con-
centrates prepared by the buffy coat method decreased (2/
15 286 vs. 10/13 488, P = 0025, Chi-square) (Fig. 3).
Increased storage lesion in apheresis platelet
concentrates with low swirling score
Next, apheresis platelet concentrates with premature low
swirling score (n = 28) were compared to regular products
expiring on day 5 with normal swirling score (n = 34).
All were routine products treated with Intercept pathogen
inactivation. Apheresis concentrates with low swirling
score contained more platelets and at a higher concentra-
tion than regular products (P < 00001, Fig. 4a,b). These
data sets had a skewed distribution towards the upper
range for products with low swirling score as shown in
the histograms in Fig. 4(c,d).
Metabolic parameters indicated increased anaerobic
metabolism in apheresis concentrates with low swirling
because the pH was decreased (P < 00001, Fig. 5a) and
lactic acid concentrations were increased (P = 00002,
Fig. 5b) compared to regular products. None of the prod-
ucts had pH levels below 64. Glucose concentrations
were inversely related to lactic acid (Fig. 5c) and far more
products had glucose levels below the detection limit
(11 mM) of the blood gas analyser (Fig. 5d) in the cohort
with premature low swirling score.
Other storage lesion parameters like MPV (Fig. 6a),
annexin V binding (Fig. 6b) and P-selectin expression
(Fig. 6c) were also significantly different (P < 00001). Pla-
telet integrin aIIbb3 in products with low swirling score was
not prematurely activated (Fig. 6d, P = 099) but
responded less to TRAP and CRP stimulation (Fig. 6e,f). We
moreover found a significant correlation (P < 00001)
between anaerobic respiration and the amount of platelets,
especially when combining the data from the premature
low swirling products and the regular products (Fig. 7).
Discussion
The implementation of Intercept pathogen inactivation for
platelets demands significant changes in the primary pro-
duction process of platelet concentrates [10]. To decrease
complexity, we chose to only use ‘Large Volume’ bag sets
[13] supplemented with a small number of ‘Dual Storage’
bag sets for paediatric purposes. Because the Belgian com-
petent authority advocated a minimal platelet dose of
30 9 1011 for pathogen-inactivated concentrates, our pri-
mary apheresis and buffy coat production processes were
adapted so to not only meet the Intercept guard bands set
Fig. 2 Glucose concentration in routine
platelet concentrates treated with Intercept
pathogen inactivation. Glucose concentration
was determined in expired (day 6) platelet
concentrate units prepared by (a) pooling of
buffy coats (○) or by (b) apheresis (●) and is
shown in function of the initial platelet count.
The dotted horizontal line represents the lower
limit (11 mM) of detection for glucose.
Fig. 3 The number of products with low swirling score before and after
introduction of pathogen inactivation. A retrospective analysis of the
number of products with a low swirling score (≤1) (filled bars) with
respect to the total number of distributed products (open bars) was per-
formed on a 12-month record before and after the introduction of Inter-
cept pathogen inactivation. Data are displayed by product type showing
apheresis products in black and buffy coat-derived platelet concentrates
in blue.
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by the manufacturer but also include the critical lower dose
limitation. Overall, this has led to platelet concentrates
with a relatively high mean platelet content.
The current study shows that platelet content alone
does not necessarily relate inversely to quality, at least in
the content ranges produced in our facilities and for
pooled buffy coat concentrates. Indeed, Intercept patho-
gen inactivation-treated concentrates prepared from six
buffy coats did not show increased incidence of low swir-
ling compared to when pathogen inactivation was not in
Fig. 4 Apheresis concentrates with poor
swirling contain more platelets than regular
products. (a) Platelet count and (b)
concentration is shown for apheresis
concentrates with abnormally low swirling
before expiration (≤1, n = 28) compared to
regular products with acceptable swirling (≥2)
on the day of expiration (n = 26). Data are
shown as box and whiskers with median (line)
and range (whiskers). (c, d) Histograms show
the platelet count and platelet concentration
distribution of apheresis concentrates with
abnormally low swirling before expiration
(filled bars) compared to regular products with
acceptable swirling on the day of expiration
(open bars). All products were treated with
Intercept pathogen inactivation.
Fig. 5 Metabolism of platelet concentrates
with low and normal swirling. (a) The pH of
apheresis concentrates with abnormally low
swirling before expiration (≤1, n = 28)
compared to regular products with acceptable
swirling (≥2) on the day of expiration (n = 26).
Data are shown as box and whiskers with
median (line) and range (whiskers). The dashed
line shows the lower limit of acceptance for
platelet concentrates. (b) The lactic acid and (c)
glucose concentration for the same samples,
depicted as dot plot with the mean (line) and
standard deviation (whiskers). The dashed
horizontal line represents the limit of detection
(11 mM) for glucose concentration
determination. (d) The number of products with
glucose levels below (filled bars) and above
(open bars) detection limit.
© 2017 The Authors.
Vox Sanguinis published by John Wiley & Sons Ltd on behalf of International Society of Blood Transfusion
Vox Sanguinis (2017)
Platelet content and pathogen inactivation 5
place. On the other hand, in the year following imple-
mentation of pathogen inactivation, a greater proportion
of apheresis platelet concentrates with high platelet con-
tent had decreased swirling compared to those prepared
from buffy coat, although none of these units had pH
levels below the 64 threshold.
The initial validation study for implementation of the
Intercept pathogen inactivation process indicated that pH
and glucose levels would decrease faster for apheresis
than for buffy coat concentrates despite comparable pla-
telet content, suggesting that apheresis predisposes to
increased storage lesion rates. However, because apheresis
units with low platelet content (16 9 1011) did not show
this, we reasoned that platelet content must combine with
apheresis to generate the effect. In a comparable valida-
tion study of Chavarin et al. [14] (n = 16), slightly
increased storage lesion rates for apheresis products com-
pared to buffy coat-derived products were also found
with product quality measures well within standards.
There are several studies that have reported on the
quality of apheresis platelet concentrates treated with
Intercept pathogen inactivation [3, 14–17]. It is important
to note that all of these studies have in common that pla-
telet contents were well below 50 9 1011 (Table 2) which
is relevant because this was the median content of
apheresis concentrates that presented with premature low
swirling. Furthermore, the published longitudinal research
studies require regular sampling in the millilitre range
Fig. 6 Storage lesion markers. (a) MPV,
(b) annexin V positive platelets, (c) expression
of P-selectin, (d) expression of activated
integrin aIIbb3 in undisturbed platelets or in
platelets activated by (e) TRAP or (f) CRP are
depicted as box plots with median (line) and
range (whiskers). Apheresis concentrates with
abnormally low swirling before expiration
(≤1, n = 28) were compared to regular
products with acceptable swirling (≥2) on the
day of expiration (n = 26). Annexin V,
P-selectin and PAC1 data were recorded by
flow cytometry and either shown as the
percentage positive cells (%) or the median
fluorescence intensity (MFI).
© 2017 The Authors.
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which significantly decreases the actual platelet content
during storage thereby potentially biasing the realistic
influence of content on storage lesion rates. Overall, the
current data set suggests that platelet content is relevant
in pathogen-inactivated apheresis concentrates especially
above 50 9 1011.
However, the actual number of apheresis concentrates
produced in our blood bank containing more than
50 9 1011 platelets is estimated to be twenty fivefold
higher than the incidence of premature low swirling. This
suggests that a noticeable change in swirling indicates
end-stage quality loss and cannot be used to monitor
ongoing deterioration. Consequently, apheresis concen-
trates with a high platelet content might have had labora-
tory signs of increased storage lesion like glucose
exhaustion or poor integrin responses but not necessarily
poor swirling. This can also be concluded from the initial
validation study where platelet concentrates with high
content had lowered pH values and glucose levels at day
5 but normal swirling. Therefore, in the context of Inter-
cept pathogen inactivation, it may be instructive to (re)
determine apheresis platelet concentrate quality in func-
tion of content especially in ranges above 50 9 1011 and
to investigate whether this influences clinical outcomes
like CCI.
Finally, it is difficult to speculate on the reasons why
apheresis but not buffy coat-derived concentrates would
be more vulnerable in this particular context and for this
outcome (low swirling), especially because differences in
typical storage lesion markers between buffy coat-derived
and apheresis-derived platelet concentrates are minor
[18, 19]. We do think that the actual platelet content in
the final (split) apheresis product is of matter and not
necessarily the targeted (high dose) one before splitting
because double-dose or triple-dose apheresis procedures
do not yield products with quickly declining quality, at
least when these are split within a couple of hours after
donation [20, 21]. In our study, there was no difference
between the number of double apheresis donations in the
non-swirling group (2/28) versus the normal swirling
group (4/26). On the same line, platelet content does not
necessarily relate in a linear fashion to pH or storage
lesion [22] in ranges below 50 9 1011 [18, 23]. However,
only when larger contents are analysed in a scatter plot
like in Fig. 7 do such correlations become apparent [24].
In conclusion, real-world quality control data have
indicated a small but significant increase in apheresis
products with premature low swirling following the intro-
duction of Intercept pathogen inactivation. This was not
observed in similarly inactivated products prepared by the
buffy coat method. Our data suggest that especially
apheresis products with a content above 50 9 1011 are at
risk indicating the need for validation in the upper guard
band range for Intercept-treated apheresis concentrates.
Fig. 7 Correlation between platelet count and
anaerobic respiration. (a) Lactic acid and (b) pH
were plotted against platelet counts in
apheresis concentrates with abnormally low
swirling before expiration (●) and regular
products with acceptable swirling on the day
of expiration (○).The dashed line shows the
lower limit of acceptance for platelet
concentrates. Spearman’s correlation coefficient
(r) is shown in the upper left corner of the
graph.
Table 2 In vitro studies on Intercept pathogen-inactivated apheresis platelet concentrates
Separator Content (31011) pH (day 5) Reference
COM.TEC (Fresenius, Bad Homburg, Germany) 262 – 027 698 – 008 Moog et al. [15]
Trima Accel (Terumo BCT, Lakewood, CO, USA) 263 – 021 693 – 004 Picker et al. [16]
Amicus (Baxter, Munich, Germany) 362 – 055 699 – 012 Janetzko et al. [3]
MCS+ (Haemonetics, Braintree, MA, USA) 372 – 042 693 – 008 Isola et al. [17]
Amicus 435 – 091 708 – 015 Chavarin et al. [14]
Trima Accel (Terumo BCT, Lakewood, CO, USA) 508 – 095 678 – 015
Data are shown as mean – SD.
© 2017 The Authors.
Vox Sanguinis published by John Wiley & Sons Ltd on behalf of International Society of Blood Transfusion
Vox Sanguinis (2017)
Platelet content and pathogen inactivation 7
Acknowledgements
This research was made possible through funding from
the Foundation for Scientific Research of the Belgian Red
Cross.
Author contributions
H.B.F., V.C. and J.C. designed research; H.B.F., K.D.P.,
J.C. and V.C. contributed to critical analytical tools,
reagents, samples or data; R.D., B.S. and H.B.F. per-
formed research and collected data; R.D., V.C. and H.B.F.
analysed and interpreted data; H.B.F. performed statisti-
cal analyses and H.B.F. and V.C. wrote the manuscript;
all authors critically reviewed and amended the manu-
script.
Conflict of interest
The authors declare no conflict of interests.
References
1 Deckmyn H, Feys HB: Assays for qual-
ity control of platelets for transfusion.
ISBT Sci Ser 2013; 8:221–224
2 Abonnenc M, Sonego G, Kaiser-
Guignard J, et al.: In vitro evaluation
of pathogen-inactivated buffy coat-
derived platelet concentrates during
storage: psoralen-based photochemical
treatment step-by-step. Blood Transfus
2015; 13:255–264
3 Janetzko K, Lin L, Eichler H, et al.:
Implementation of the INTERCEPT
Blood System for platelets into routine
blood bank manufacturing procedures:
evaluation of apheresis platelets. Vox
Sang 2004; 86:239–245
4 Apelseth TO, Bruserud O, Wentzel-Lar-
sen T, et al.: In vitro evaluation of meta-
bolic changes and residual platelet
responsiveness in photochemical treated
and gamma-irradiated single-donor pla-
telet concentrates during long-term
storage. Transfusion 2007; 47:653–665
5 Van Aelst B, Feys HB, Devloo R, et al.:
Riboflavin and amotosalen photochemi-
cal treatments of platelet concentrates
reduce thrombus formation kinetics
in vitro. Vox Sang 2015; 108:328–339
6 Van Aelst B, Devloo R, Zachee P, et al.:
Psoralen and ultraviolet a light treat-
ment directly affects phosphatidylinosi-
tol 3-kinase signal transduction by
altering plasma membrane packing.
J Biol Chem 2016; 291:24364–24376
7 van Rhenen D, Gulliksson H, Cazenave
JP, et al.: Transfusion of pooled buffy
coat platelet components prepared
with photochemical pathogen inacti-
vation treatment: the euroSPRITE trial.
Blood 2003; 101:2426–2433
8 McCullough J, Vesole DH, Benjamin
RJ, et al.: Therapeutic efficacy and
safety of platelets treated with a
photochemical process for pathogen
inactivation: the SPRINT Trial. Blood
2004; 104:1534–1541
9 Butler C, Doree C, Estcourt LJ, et al.:
Pathogen-reduced platelets for the
prevention of bleeding. Cochrane
Database Syst Rev 2013; 3:CD009072
10 van der Meer PF, Couture C, Hervig T,
et al.: Experiences with semi-routine
production of riboflavin and UV-B
pathogen-inactivated platelet concen-
trates in three blood centres. Vox Sang
2017; 112:9–17
11 Hardwick J: Blood processing. ISBT
Sci Ser 2008; 3:148–176
12 Goodall AH, Appleby J: Flow-cytometric
analysis of platelet-membrane glycopro-
tein expression and platelet activation.
Methods Mol Biol 2004; 272:225–253
13 Irsch J, Lin L: Pathogen inactivation of
platelet and plasma blood components
for transfusion using the INTERCEPT
Blood System. Transfus Med Hemother
2011; 38:19–31
14 Chavarin P, Cognasse F, Argaud C,
et al.: In vitro assessment of apheresis
and pooled buffy coat platelet compo-
nents suspended in plasma and SSP+
photochemically treated with amotos-
alen and UVA for pathogen inactiva-
tion (INTERCEPT Blood SystemTM). Vox
Sang 2011; 100:247–249
15 Moog R, Frohlich A, Mayaudon V,
et al.: In vitro evaluation of COM.TEC
apheresis platelet concentrates using a
preparation set and pathogen inactiva-
tion over a storage period of five days.
J Clin Apher 2004; 19:185–191
16 Picker SM, Oustianskaia L, Schneider
V, et al.: Functional characteristics of
apheresis-derived platelets treated with
ultraviolet light combined with either
amotosalen-HCl (S-59) or riboflavin
(vitamin B2) for pathogen-reduction.
Vox Sang 2009; 97:26–33
17 Isola H, Kientz D, Aleil B, et al.: In
vitro evaluation of Haemonetics MCS+
apheresis platelet concentrates treated
with photochemical pathogen inactiva-
tion following plasma volume reduc-
tion using the INTERCEPT Preparation
Set. Vox Sang 2006; 90:128–130
18 Mitchell SG, Turner VS, Hawker RJ,
et al.: A comparative study in volun-
teers of apheresis and buffy coat derived
platelets. Platelets 1995; 6:146–151
19 Krailadsiri P, Seghatchian J: Are all leu-
codepleted platelet concentrates equiva-
lent? Vox Sang 2000; 78:171–175
20 Macher S, Sipurzynski-Budraß S, Rosskopf
K, et al.: Function and activation state of
platelets in vitro depend on apheresis
modality.Vox Sang 2010; 99:332–340
21 Picker SM, Steisel A, Gathof BS: Cell
integrity and mitochondrial function
after Mirasol-PRT treatment for patho-
gen reduction of apheresis-derived plate-
lets: results of a three-arm in vitro study.
Transfus Apher Sci 2009; 40:79–85
22 Heaton WA: In-vivo and in-vitro eval-
uation of stored platelet products; in
Lozano M, Sweeney JD (eds): Platelet
Transfusion Therapy. Bethesda, MD,
AABB Press, 2013:177–227
23 B€ock M, Rahrig S, Kunz D, et al.: Pla-
telet concentrates derived from buffy
coat and apheresis: biochemical and
functional differences. Transfus Med
2002; 12:317–324
24 Wagner SJ, Skripchenko A, Myrup A,
et al.: Evaluation of in vitro storage
properties of prestorage pooled whole
blood-derived platelets suspended in 100
percent plasma and treated with amotos-
alen and long-wavelength ultraviolet
light. Transfusion 2009; 49:704–710
© 2017 The Authors.
Vox Sanguinis published by John Wiley & Sons Ltd on behalf of International Society of Blood Transfusion
Vox Sanguinis (2017)
8 H. B. Feys et al.
